MAD Refractory: Solid Tumor QD w/o Break
NCT00207012 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45
Last updated 2010-03-02
Summary
This is a continuous dosing Phase I Study of BMS-599626 in patients with HER2-expressing advanced solid malignancies.
Conditions
- HER2 or EGFR Expressing Advanced Solid Malignancies
Interventions
- DRUG
-
BMS-599626
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-05-31
- Primary Completion
- 2006-02-28
Countries
- France
- Spain
Study Locations
More Related Trials
-
A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors
NCT05461768 ·Status: RECRUITING ·Phase: PHASE1
-
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
NCT06714617 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors
NCT06503783 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer
NCT06957886 ·Status: RECRUITING ·Phase: PHASE3
-
Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Positive Solid Tumors (Anti HER2 Fcab)
NCT02286219 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer
NCT06471205 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid Tumors
NCT05339685 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study to Observe Treatment Patterns and Outcomes in Participants in Saudi Arabia With Human Epidermal Growth Factor Receptor 2 (HER2-Positive) Unresectable Locally Advanced or Metastatic Breast Cancer (LA/mBC)
NCT02611310 ·Status: TERMINATED
-
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)
NCT06343948 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
NCT02595762 ·Status: COMPLETED
-
A Study of DP303c in Patients With HER2-positive Advanced Solid Tumors
NCT05810103 ·Status: UNKNOWN ·Phase: PHASE1
-
DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer
NCT05334810 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of DP303c Administered Intravenously to Subjects With HER2-Positive in Advanced Solid Tumors
NCT04146610 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer
NCT06188559 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)
NCT06382142 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC
NCT06439771 ·Status: RECRUITING ·Phase: PHASE2
-
A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance
NCT07321015 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
NCT05470348 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer
NCT02131506 ·Status: TERMINATED ·Phase: PHASE1
-
DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer
NCT06313086 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)
NCT07208149 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer
NCT05629949 ·Status: COMPLETED ·Phase: PHASE3
-
Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer
NCT02338531 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors
NCT05625412 ·Status: COMPLETED ·Phase: PHASE1
-
Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies
NCT07309770 ·Status: RECRUITING ·Phase: PHASE2